FDA Approves Generic Anti-Arrhythmic Drug

Article

Generic dofetilide capsules approved to treat atrial fibrillation and atrial flutter.

The FDA recently approved an Abbreviated New Drug Application (ANDA) for dofetilide capsules and have granted Mayne Pharma market exclusivity for 180 days.

The approved drug is a generic version of Tikosyn, which is an anti-arrhythmic drug used to treat irregular heartbeats, according to the Mayne Pharma press release.

Because Mayne Pharma was the first pharmaceutical company to file a completed ANDA, the FDA granted the company market exclusivity. According to the press release, they will begin selling the dofetilide capsules immediately.

The FDA also has recently withdrawn the Tikosyn Risk Evaluation and Mitigation Strategies program, which means that the availability of dofetilide capsules will not be limited.

Related Videos
Doctor using a stethoscope checking patient with examining, presenting results symptom and recommend treatment method, Healthcare and medical concept - Image credit: Ngampol | stock.adobe.com
A panel of 5 experts on ASCVD
A panel of 5 experts on ASCVD
A panel of 5 experts on ASCVD
A panel of 5 experts on ASCVD
A panel of 5 experts on ASCVD
A panel of 5 experts on ASCVD
© 2024 MJH Life Sciences

All rights reserved.